This federal Project Grant award, valued at $152,135 and awarded by the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development program), supports research by the University of Texas Health Science Center at Houston (UTHealth) to unravel RB1-mediated enhancer control and chromatin architecture in osteosarcoma gene transcription. The award will fund a 2-year research project from September 1, 2024 to August 31, 2026 to advance scientific understanding of the molecular mechanisms underlying osteosarcoma, a rare type of bone cancer. This research aligns with the program's objectives to transform healthcare for military service members and the public through innovative biomedical studies.
Generated 1/28/25, 9:35 AM